In line with the late-stage patients, aggressive types of CTCL, including SS, are governed by a predominant Th2-type immune response reflected by aberrant secretion of the Th2-type cytokine, IL-4, and decreased production of Th1-associated cytokines, including IL-12 and IFN-γ [41]. Here, IFNG is linked to primary cutaneous T-cell non-Hodgkin lymphoma.